Published date: 28 November 2016
This notice was replaced on 22 December 2016
This notice does not contain the most up-to-date information about this procurement. The most recent notice is:
Awarded contract (published 22 December 2016)
Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.
Contract summary
Industry
Health and social work services - 85000000
Location of contract
East Midlands
Value of contract
£88,000 to £1,500,000
Procurement reference
NGH001-DN220405-82099297
Published date
28 November 2016
Closing date
3 December 2016
Contract start date
5 December 2016
Contract end date
21 December 2020
Contract type
Supply contract
Procedure type
Accelerated restricted procedure
This is an accelerated procedure.
Contract is suitable for SMEs?
Yes
Contract is suitable for VCSEs?
Yes
Description
NGHT has had to publish a VEAT notice for the following therapy:
Xofigo (Radium 223) Dose.
The reason for the VEAT notice was due to:
"There was a palliative treatment called Strontium that could be used for bone pain, however this involved some significant side-effects and hence it has not been used for a number of years.
This new treatment (Radium 223) has been shown to significantly improve overall survival for this group of patients. (ALSYMPCA trial). Currently these patients are either sent elsewhere for the same treatment, or they do not receive treatment.
This is the only radiopharmaceutical that has been granted NICE approval for treatment of bone metastasis, and is the only Radium (223) product currently available commercially.
About the buyer
Contact name
Paul Scotland
Address
Northampton General Hospital
Cliftonville
Northampton
NN1 5BD
England
Telephone
+44 1604544401
Website
Share this notice
All content is available under the
